Kidney cancer isn’t the only disease area where Merck’s Keytruda is moving in to challenge Bristol-Myers Squibb’s Opdivo.
After failing a phase 2 in solid-organ transplant patients, the CMV vaccine failed in hematopoietic cell transplant recipients too.
The commercial life for Novartis’ chronic lymphocytic leukemia drug Arzerra outside the U.S. is coming to an end.
On Friday, a DOJ official signaled what his agency might do next in the yearslong generic drug price fixing probe.
Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company seals the deal with Celgene.
The hyperpersonalization trend means pharmarketers are going to use advanced data and analytics to target audiences as small as one.
Tweeting to the top, GlaxoSmithKline and Pfizer tied for the No. 1 spot in the inaugural ranking of global pharma influencers by Owen Health.
Teva was hoping to level the convenience playing field in severe asthma with a subcutaneous version of Cinqair. But those plans have hit a snag.
Sanofi finally scored a deal. It plans to shell out $11.6 billion for Bioverativ, the hemophilia-focused drugmaker spun off by Biogen just last year.
CSL may have faced resistance from Shire when it launched Haegarda last year, but CEO Paul Perreault says the decision to go ahead was worth it.